Switch to:
Also traded in: Germany, Sweden, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 1.64
SWTUY's Cash-to-Debt is ranked lower than
58% of the 200 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.44 vs. SWTUY: 1.64 )
Ranked among companies with meaningful Cash-to-Debt only.
SWTUY' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01  Med: 0.79 Max: No Debt
Current: 1.64
Equity-to-Asset 0.55
SWTUY's Equity-to-Asset is ranked lower than
60% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.59 vs. SWTUY: 0.55 )
Ranked among companies with meaningful Equity-to-Asset only.
SWTUY' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.48  Med: 0.71 Max: 0.77
Current: 0.55
0.48
0.77
Interest Coverage 11.45
SWTUY's Interest Coverage is ranked lower than
65% of the 130 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 54.16 vs. SWTUY: 11.45 )
Ranked among companies with meaningful Interest Coverage only.
SWTUY' s Interest Coverage Range Over the Past 10 Years
Min: 0.79  Med: 2 Max: No Debt
Current: 11.45
Piotroski F-Score: 6
Altman Z-Score: 5.27
Beneish M-Score: -1.90
WACC vs ROIC
10.87%
16.41%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 22.24
SWTUY's Operating Margin % is ranked higher than
91% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.88 vs. SWTUY: 22.24 )
Ranked among companies with meaningful Operating Margin % only.
SWTUY' s Operating Margin % Range Over the Past 10 Years
Min: -33.86  Med: -1.69 Max: 22.24
Current: 22.24
-33.86
22.24
Net Margin % 14.82
SWTUY's Net Margin % is ranked higher than
89% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.64 vs. SWTUY: 14.82 )
Ranked among companies with meaningful Net Margin % only.
SWTUY' s Net Margin % Range Over the Past 10 Years
Min: -29.4  Med: -1.67 Max: 14.82
Current: 14.82
-29.4
14.82
ROE % 14.03
SWTUY's ROE % is ranked higher than
80% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.95 vs. SWTUY: 14.03 )
Ranked among companies with meaningful ROE % only.
SWTUY' s ROE % Range Over the Past 10 Years
Min: -24.5  Med: -0.78 Max: 14.03
Current: 14.03
-24.5
14.03
ROA % 8.16
SWTUY's ROA % is ranked higher than
80% of the 203 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.53 vs. SWTUY: 8.16 )
Ranked among companies with meaningful ROA % only.
SWTUY' s ROA % Range Over the Past 10 Years
Min: -14.82  Med: -0.6 Max: 8.16
Current: 8.16
-14.82
8.16
ROC (Joel Greenblatt) % 249.99
SWTUY's ROC (Joel Greenblatt) % is ranked higher than
96% of the 200 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.23 vs. SWTUY: 249.99 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
SWTUY' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -59.86  Med: -4.1 Max: 249.99
Current: 249.99
-59.86
249.99
3-Year Revenue Growth Rate 18.50
SWTUY's 3-Year Revenue Growth Rate is ranked higher than
88% of the 129 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.20 vs. SWTUY: 18.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
SWTUY' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -34.2  Med: -9.4 Max: 18.5
Current: 18.5
-34.2
18.5
GuruFocus has detected 1 Warning Sign with Swedish Orphan Biovitrum AB $SWTUY.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» SWTUY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with SWTUY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research  
Compare:NYSE:ALR, NAS:PRXL, NAS:VWR, OTCPK:CZMWY, NAS:PRAH, NYSE:CRL, NAS:BRKR, NAS:INCR, NAS:NEOG, NAS:ICLR, NAS:EXAS, NAS:MEDP, NYSE:BIO.B, NAS:MYGN, NAS:KANG, NAS:AXDX, NAS:ABAX, NAS:ALOG, NAS:GHDX, NAS:FMI » details
Traded in other countries:B6E.Germany, SOBI.Sweden, 0MTD.UK,
Swedish Orphan Biovitrum AB is an international speciality healthcare company dedicated to rare diseases. The Company's Therapeutic Areas are Inflammation and Genetics & Metabolism, with a growing focus on Haemophilia and Neonatology.

Swedish Orphan Biovitrum AB is a Sweden-based pharmaceutical company that markets specialist pharmaceuticals. Its research and development is focused on the development and production of biotechnology therapeutics within the areas of hemophilia, inflammation/autoimmune diseases, cancer supportive care, and malabsorption. The company produces specialist pharmaceuticals that are intended to target small patient groups and are prescribed by medical specialists, as well as biopharmaceuticals, recombinant proteins produced using biotechnological processes similar to the body's own substances. The company develops its products either internally, or through partnerships with other pharmaceutical companies. Biovitrium promotes its proprietary products and prescription specialist products throughout Europe, North America, Australia, and New Zealand, in collaboration with Wyeth, Amgen, and other pharmaceutical and biotechnology comapanies. The company's pipeline includes the following products: Kepivance, a recombinant protein drug used to prevent inflammation and ulcers of the oral mucosa in patients suffering from hematologic cancer; Kiobrina, a recombinant human lipid-digesting enzyme (BSSL) for the purpose of improving fat absorption and increasing growth in premature infants; Exinalda, a biotechnologically produced recombinant human enzyme to improve treatment for patients suffering from fat malabsorption due to pancreatic insufficiency in diseases such as cystic fibrosis (CF); Factor IX Fc, a recombinant protein drug developed in combination with Biogen Idec for the treatment of hemophilia B, to name a few.

Ratios

vs
industry
vs
history
PE Ratio 45.31
SWTUY's PE Ratio is ranked lower than
66% of the 107 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.58 vs. SWTUY: 45.31 )
Ranked among companies with meaningful PE Ratio only.
SWTUY' s PE Ratio Range Over the Past 10 Years
Min: 21.76  Med: 149 Max: 3687
Current: 45.31
21.76
3687
PE Ratio without NRI 45.31
SWTUY's PE Ratio without NRI is ranked lower than
65% of the 100 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.65 vs. SWTUY: 45.31 )
Ranked among companies with meaningful PE Ratio without NRI only.
SWTUY' s PE Ratio without NRI Range Over the Past 10 Years
Min: 21.76  Med: 149 Max: 3687
Current: 45.31
21.76
3687
Price-to-Owner-Earnings 35.50
SWTUY's Price-to-Owner-Earnings is ranked lower than
62% of the 61 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.11 vs. SWTUY: 35.50 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
SWTUY' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 26.03  Med: 55.13 Max: 1236.84
Current: 35.5
26.03
1236.84
PB Ratio 5.90
SWTUY's PB Ratio is ranked lower than
69% of the 209 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.65 vs. SWTUY: 5.90 )
Ranked among companies with meaningful PB Ratio only.
SWTUY' s PB Ratio Range Over the Past 10 Years
Min: 0.71  Med: 4.43 Max: 8.06
Current: 5.9
0.71
8.06
PS Ratio 6.70
SWTUY's PS Ratio is ranked lower than
66% of the 205 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.42 vs. SWTUY: 6.70 )
Ranked among companies with meaningful PS Ratio only.
SWTUY' s PS Ratio Range Over the Past 10 Years
Min: 1.07  Med: 5.62 Max: 12.77
Current: 6.7
1.07
12.77
Price-to-Free-Cash-Flow 153.39
SWTUY's Price-to-Free-Cash-Flow is ranked lower than
92% of the 73 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.89 vs. SWTUY: 153.39 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
SWTUY' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 12.24  Med: 113.39 Max: 861.74
Current: 153.39
12.24
861.74
Price-to-Operating-Cash-Flow 96.40
SWTUY's Price-to-Operating-Cash-Flow is ranked lower than
97% of the 87 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.57 vs. SWTUY: 96.40 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
SWTUY' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 10.25  Med: 56.39 Max: 1072.22
Current: 96.4
10.25
1072.22
EV-to-EBIT 29.92
SWTUY's EV-to-EBIT is ranked lower than
63% of the 105 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.83 vs. SWTUY: 29.92 )
Ranked among companies with meaningful EV-to-EBIT only.
SWTUY' s EV-to-EBIT Range Over the Past 10 Years
Min: -600.4  Med: -9.5 Max: 627.6
Current: 29.92
-600.4
627.6
EV-to-EBITDA 21.62
SWTUY's EV-to-EBITDA is ranked lower than
64% of the 112 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.07 vs. SWTUY: 21.62 )
Ranked among companies with meaningful EV-to-EBITDA only.
SWTUY' s EV-to-EBITDA Range Over the Past 10 Years
Min: -600.4  Med: 19 Max: 1429.9
Current: 21.62
-600.4
1429.9
Current Ratio 1.78
SWTUY's Current Ratio is ranked lower than
69% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.60 vs. SWTUY: 1.78 )
Ranked among companies with meaningful Current Ratio only.
SWTUY' s Current Ratio Range Over the Past 10 Years
Min: 1.67  Med: 2.58 Max: 3.23
Current: 1.78
1.67
3.23
Quick Ratio 1.24
SWTUY's Quick Ratio is ranked lower than
77% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.21 vs. SWTUY: 1.24 )
Ranked among companies with meaningful Quick Ratio only.
SWTUY' s Quick Ratio Range Over the Past 10 Years
Min: 0.66  Med: 1.48 Max: 1.89
Current: 1.24
0.66
1.89
Days Inventory 200.84
SWTUY's Days Inventory is ranked lower than
85% of the 158 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 88.66 vs. SWTUY: 200.84 )
Ranked among companies with meaningful Days Inventory only.
SWTUY' s Days Inventory Range Over the Past 10 Years
Min: 84.33  Med: 310.58 Max: 566.43
Current: 200.84
84.33
566.43
Days Sales Outstanding 48.49
SWTUY's Days Sales Outstanding is ranked higher than
72% of the 160 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 64.91 vs. SWTUY: 48.49 )
Ranked among companies with meaningful Days Sales Outstanding only.
SWTUY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 10.26  Med: 55.08 Max: 73.93
Current: 48.49
10.26
73.93

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -0.30
SWTUY's 3-Year Average Share Buyback Ratio is ranked higher than
79% of the 120 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.20 vs. SWTUY: -0.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
SWTUY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -68.1  Med: -24.3 Max: 0.1
Current: -0.3
-68.1
0.1

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 5.10
SWTUY's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
79% of the 68 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.11 vs. SWTUY: 5.10 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
SWTUY' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 4.45  Med: 5.94 Max: 8.54
Current: 5.1
4.45
8.54
Price-to-Median-PS-Value 1.19
SWTUY's Price-to-Median-PS-Value is ranked lower than
62% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.06 vs. SWTUY: 1.19 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
SWTUY' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.2  Med: 1.02 Max: 1.98
Current: 1.19
0.2
1.98
Earnings Yield (Greenblatt) % 3.30
SWTUY's Earnings Yield (Greenblatt) % is ranked higher than
71% of the 226 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.50 vs. SWTUY: 3.30 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
SWTUY' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.2  Med: 0.8 Max: 5
Current: 3.3
0.2
5

More Statistics

Revenue (TTM) (Mil) $562.6
EPS (TTM) $ 0.31
Beta1.73
Short Percentage of Float0.00%
52-Week Range $10.25 - 15.49
Shares Outstanding (Mil)268.75

Analyst Estimate

Dec16 Dec18 Dec19
Revenue (Mil $) 561 677 751
EPS ($) 0.33 0.41 0.56
EPS without NRI ($) 0.33 0.41 0.56
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for SWTUY

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Swedish Orphan Biovitrum AB :SWTUY-US: Earnings Analysis: 2016 By the Numbers : February 22, 2017 Feb 22 2017
Swedish Orphan Biovitrum AB :SWTUY-US: Earnings Analysis: Q4, 2016 By the Numbers : February 21,... Feb 21 2017
Sobi™ Enters Into new Distribution Agreement With Valeant for Ammonul® Feb 21 2017
Swedish Orphan Biovitrum AB - Statement Regarding Speculations on a Potential Sale of the Partner... Feb 03 2017
Swedish Orphan Biovitrum AB - Invitation - Presentation of Sobi's Q4 and FY 2016 Results Feb 03 2017
Swedish Orphan Biovitrum AB - Long-term Safety and Efficacy Data of Extended Half-life Therapy... Feb 02 2017
Sobi Obtains Approval From the European Commission for new Dosing Frequency of Orfadin® Feb 02 2017
Sobi and Bioverativ to Reveal new Long-term Safety and Efficacy Data of Elocta® and Alprolix® at... Feb 01 2017
Swedish Orphan Biovitrum AB: First Patients Enrolled in 24 Month Real-world Study Evaluating... Jan 19 2017
CEO Geoffrey McDonough to Leave Sobi Jan 09 2017
Armin Reininger Joins Sobi as Senior Vice President, Head of Global Medical and Scientific Affairs Jan 05 2017
Sobi and Horizon Pharma enter five-year distribution agreement for Ravicti® and Ammonaps® outside... Dec 07 2016
Swedish Orphan Biovitrum AB :SWTUY-US: Earnings Analysis: Q3, 2016 By the Numbers : November 7, 2016 Nov 07 2016
Swedish Orphan Biovitrum AB :SWTUY-US: Earnings Analysis: Q2, 2016 By the Numbers : July 22, 2016 Jul 22 2016
FDA approves a new dosing option of ORFADIN® (nitisinone) -- 20 mg Capsule Jun 15 2016
Swedish Orphan Biovitrum AB :SWTUY-US: Earnings Analysis: Q1, 2016 By the Numbers May 03 2016
FDA approves ORFADIN® (nitisinone) Oral Suspension Apr 26 2016
Swedish Orphan Biovitrum AB Earnings Analysis: Q4, 2015 By the Numbers Mar 02 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)